The current price of CYBN is $8.28 — it has increased by 1.22% since the previous close. Data as of Jan 2, 2026.
CYBN is flat over the past week, flat over the past month and down 15.85% over the past year. The price is above its 200-day moving average of $6.99.
Of the 7 analysts covering Cybin Inc., 7 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Cybin Inc. has a market capitalization of $413.02M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
Cybin Inc. has not paid any dividends over the past year.
Companies most comparable to Cybin Inc. include Alector, Inc., PepGen Inc., Innate Pharma S.A., Molecular Partners AG and Nkarta, Inc.
In the latest trading session CYBN moved between $8.14 and $8.38, a range of 2.91% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Cybin Inc. shows a buy rating today and a neutral rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Cybin Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks CYBN has traded between $5.50 and $9.12. The current price is 9.21% below its 52-week high.
Figures as of Jan 2, 2026. This information is provided for general purposes only and is not investment advice.